GEP20207092B - Novel phosphinane and azaphosphinane derivatives, method for preparing same and pharmaceutical compositions containing same - Google Patents

Novel phosphinane and azaphosphinane derivatives, method for preparing same and pharmaceutical compositions containing same

Info

Publication number
GEP20207092B
GEP20207092B GEAP201714853A GEAP2017014853A GEP20207092B GE P20207092 B GEP20207092 B GE P20207092B GE AP201714853 A GEAP201714853 A GE AP201714853A GE AP2017014853 A GEAP2017014853 A GE AP2017014853A GE P20207092 B GEP20207092 B GE P20207092B
Authority
GE
Georgia
Prior art keywords
pharmaceutical compositions
same
azaphosphinane
phosphinane
derivatives
Prior art date
Application number
GEAP201714853A
Other languages
English (en)
Inventor
Laboratoires Servier Les
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55752640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GEP20207092(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of GEP20207092B publication Critical patent/GEP20207092B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6568Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65842Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65842Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
    • C07F9/65846Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a six-membered ring which may be condensed with another ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
GEAP201714853A 2016-01-14 2017-01-13 Novel phosphinane and azaphosphinane derivatives, method for preparing same and pharmaceutical compositions containing same GEP20207092B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1670004A FR3046793B1 (fr) 2016-01-14 2016-01-14 Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
GEP20207092B true GEP20207092B (en) 2020-04-10

Family

ID=55752640

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP201714853A GEP20207092B (en) 2016-01-14 2017-01-13 Novel phosphinane and azaphosphinane derivatives, method for preparing same and pharmaceutical compositions containing same

Country Status (47)

Country Link
US (2) US10138260B2 (enExample)
EP (1) EP3271368B1 (enExample)
JP (1) JP2019504070A (enExample)
KR (1) KR20180101522A (enExample)
CN (1) CN108495857A (enExample)
AR (1) AR107433A1 (enExample)
AU (1) AU2017207003B2 (enExample)
BR (1) BR112018014020A2 (enExample)
CA (1) CA3011184C (enExample)
CL (1) CL2018001862A1 (enExample)
CO (1) CO2018007271A2 (enExample)
CU (1) CU20180072A7 (enExample)
CY (1) CY1121154T1 (enExample)
DK (1) DK3271368T3 (enExample)
DO (1) DOP2018000165A (enExample)
EA (1) EA035072B1 (enExample)
EC (1) ECSP18051972A (enExample)
ES (1) ES2709376T3 (enExample)
FR (1) FR3046793B1 (enExample)
GE (1) GEP20207092B (enExample)
HK (1) HK1244283B (enExample)
HR (1) HRP20190193T1 (enExample)
HU (1) HUE042924T2 (enExample)
IL (1) IL260425B (enExample)
JO (1) JO3660B1 (enExample)
LT (1) LT3271368T (enExample)
MA (1) MA41798B1 (enExample)
MD (1) MD3271368T2 (enExample)
ME (1) ME03305B (enExample)
MX (1) MX367319B (enExample)
NI (1) NI201800073A (enExample)
PE (1) PE20181503A1 (enExample)
PH (1) PH12018501373A1 (enExample)
PL (1) PL3271368T3 (enExample)
PT (1) PT3271368T (enExample)
RS (1) RS58338B1 (enExample)
RU (1) RU2729641C2 (enExample)
SG (1) SG11201805757WA (enExample)
SI (1) SI3271368T1 (enExample)
SV (1) SV2018005721A (enExample)
TN (1) TN2018000226A1 (enExample)
TR (1) TR201820430T4 (enExample)
TW (1) TWI625334B (enExample)
UA (1) UA121275C2 (enExample)
UY (1) UY37072A (enExample)
WO (1) WO2017121969A1 (enExample)
ZA (1) ZA201804391B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3046793B1 (fr) * 2016-01-14 2018-01-05 Les Laboratoires Servier Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03001425A (es) * 2000-08-17 2003-06-06 Pfizer Compuestos farmaceuticos.
SE0103272D0 (sv) * 2001-09-28 2001-09-28 Astrazeneca Ab Chemical compounds
AU2002249275A1 (en) * 2002-03-08 2003-09-22 Warner-Lambert Company Llc Oxo azabicyclic compounds
US7420000B2 (en) * 2003-09-10 2008-09-02 University Of Southern California Amino phosphonate and amino bis-phosphonate derivatives
US20050143349A1 (en) * 2003-12-17 2005-06-30 Quatrx Pharmaceuticals Co. Phosphorus containing compounds useful for the regulation of LDL and Lp(a) levels
EP1874322A1 (en) * 2005-04-18 2008-01-09 Bayer Schering Pharma Aktiengesellschaft Use of tafi inhibitors for enhanced myocardial reperfusion and facilitated pci
US8367706B2 (en) * 2007-06-20 2013-02-05 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
FR2920773B1 (fr) * 2007-09-11 2009-10-23 Servier Lab Derives de 1,2,4,5-tetrahydro-3h-benzazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2947266B1 (fr) * 2009-06-26 2011-06-17 Servier Lab Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
BR112012005438A2 (pt) * 2009-09-09 2018-03-20 Gilead Sciences Inc inibidores de vírus flaviviridae
MX2015000830A (es) * 2012-07-18 2015-10-26 Sunshine Lake Pharma Co Ltd Derivados heterociclicos nitrogenosos y su aplicacion en farmacos.
FR3046793B1 (fr) * 2016-01-14 2018-01-05 Les Laboratoires Servier Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
SV2018005721A (es) 2018-09-06
EA201891599A1 (ru) 2019-01-31
TN2018000226A1 (fr) 2019-10-04
JO3660B1 (ar) 2020-08-27
CO2018007271A2 (es) 2018-07-19
ES2709376T3 (es) 2019-04-16
US10138260B2 (en) 2018-11-27
FR3046793B1 (fr) 2018-01-05
WO2017121969A1 (fr) 2017-07-20
CA3011184A1 (fr) 2017-07-20
CL2018001862A1 (es) 2018-10-05
US10654878B2 (en) 2020-05-19
DOP2018000165A (es) 2018-09-15
FR3046793A1 (fr) 2017-07-21
CN108495857A (zh) 2018-09-04
MX2018008639A (es) 2018-11-19
AU2017207003B2 (en) 2020-10-08
PE20181503A1 (es) 2018-09-18
SG11201805757WA (en) 2018-08-30
PL3271368T3 (pl) 2019-04-30
AU2017207003A1 (en) 2018-07-26
ECSP18051972A (es) 2018-07-31
RU2729641C2 (ru) 2020-08-11
UA121275C2 (uk) 2020-04-27
UY37072A (es) 2017-07-31
MA41798B1 (fr) 2018-11-30
RU2018129027A (ru) 2020-02-14
TW201726697A (zh) 2017-08-01
RS58338B1 (sr) 2019-03-29
HK1244283B (zh) 2019-11-22
KR20180101522A (ko) 2018-09-12
AR107433A1 (es) 2018-05-02
PH12018501373B1 (en) 2019-02-27
EP3271368A1 (fr) 2018-01-24
US20180016288A1 (en) 2018-01-18
RU2018129027A3 (enExample) 2020-03-19
BR112018014020A2 (pt) 2018-12-11
ME03305B (me) 2019-10-20
PH12018501373A1 (en) 2019-02-27
MX367319B (es) 2019-08-15
MA41798A (fr) 2018-01-24
LT3271368T (lt) 2018-12-10
AU2017207003A2 (en) 2018-10-04
US20190031693A1 (en) 2019-01-31
IL260425B (en) 2020-05-31
HRP20190193T1 (hr) 2019-04-05
SI3271368T1 (sl) 2019-02-28
DK3271368T3 (da) 2019-02-25
NI201800073A (es) 2018-09-06
TWI625334B (zh) 2018-06-01
CA3011184C (fr) 2020-09-29
HUE042924T2 (hu) 2019-07-29
MD3271368T2 (ro) 2019-03-31
TR201820430T4 (tr) 2019-01-21
EP3271368B1 (fr) 2018-10-31
ZA201804391B (en) 2020-01-29
JP2019504070A (ja) 2019-02-14
EA035072B1 (ru) 2020-04-23
CY1121154T1 (el) 2020-05-29
CU20180072A7 (es) 2018-10-04
PT3271368T (pt) 2018-12-04

Similar Documents

Publication Publication Date Title
PH12020500195A1 (en) Pyrimidinones as factor xia inhibitors
GEP20227428B (en) Heterocyclic compounds as immunomodulators
EA201890318A1 (ru) СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
MX2020007265A (es) Derivados de rapamicina.
MX2016016516A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX2021014531A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
GEP20207111B (en) Heteroaryl compounds for kinase inhibition
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
EA201792214A1 (ru) Соединения замещенного хиназолина
PH12016501338A1 (en) Indazole compounds as irak4 inhibitors
NZ729005A (en) Aminopyrimidinyl compounds as jak inhibitors
EA201691428A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
MX2016016538A (es) Derivados de quinazolinona como inhibidores de fosfatidilinositol 3-cinasa.
MX2016014728A (es) Dihidroquinolizidinonas novedosas para el tratamiento y profilaxis de la infeccion con virus de la hepatitis b.
MX2016016528A (es) Inhibidores de fosfatidilinositol 3-quinasa.
MD4794B1 (ro) Derivaţi de chinolizină substituiţi utili ca inhibitori de integrază HIV
MX2018008095A (es) Compuestos heterociclicos triciclicos condensados como inhibidores de integrasa del vih.
NZ726638A (en) Phosphatidylinositol 3-kinase inhibitors
PH12019500875B1 (en) Pyridone compound as c-met inhibitor
GEP20207058B (en) Imidazopyrazinones as pde1 inhibitors
PH12017501699B1 (en) Fused bicyclic heteroaryl derivatives having activity as phd inhibitors
PH12017500029A1 (en) 4,5-dihydroisoxazole derivatives as nampt inhibitors
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
TN2016000459A1 (en) Cycloalkyl-linked diheterocycle derivatives.
GEP20207092B (en) Novel phosphinane and azaphosphinane derivatives, method for preparing same and pharmaceutical compositions containing same